Archives: Agenda

Pharma’s multi-billion dollar investments in Omnichannel Personalization, Generative AI, and Digital Health Transformation are failing to deliver their promised ROI when accessible design is absent.

When digital touchpoints assume an “ideal user” without visual, motor, auditory, or cognitive impairments, they systematically exclude up to half of the adult patient population, particularly older adults and those managing chronic conditions.

Accessibility at Scale is not a post-launch IT check; it is the fundamental architecture that turns digital transformation investments into measurable patient health outcomes, trial retention, and brand trust.

• How to expand focus beyond core manufacturing to master late-stage packaging, multi-market labeling and ultra-cold chain logistics
• How to build connected workflows by aligning client-vendor QMS and governance structures to eliminate communication silos
• Shifting from a transactional vendor relationship to a strategic alliance that accelerates speed-to-market and mitigates supply chain risk

• Understanding the Pharmacy Card Model
• The Program Lifecycle: From Design to Delivery
• A day in the Life: Sponsors & Sites
• Proof of Performance: Feedback and Case Studies

• How to implement Lean & Six Sigma methodologies to eliminate ineffi ciencies before attempting to digitalize
• How to optimize and streamline current workflows to ensure AI models automate high-value processes, not bad habits
• How to shift focus from a traditional organizational chart to a dynamic operating model designed to support and deliver AI capabilities

Moderator: Vendor opportunity

Expert: Irena Maksimovic, Cell Therapy Drug Product Operations Performance Transformation Lead, Bristol Myers Squibb
Expert: Carol Shultz, Senior Director, Global Clinical Supply, Merck
Expert: Manish Gang, Associate Director, IT Applications, Hikma Pharmaceuticals
Expert: Frank Leu, CEO, Novapeutics

• Why throwing more AI at fragmented systems cannot fix inconsistent, non-reproducible data, and how to build a base for trusted outputs! 
• The importance of avoiding the dangers of fragmented data, including hallucination risks, brittle integrations, and compromised regulatory audit trails
• RTSM, Forecasting, and Inventory systems need a unified model across Study, Subject, Product, Execution, and Organization data, not data mappings

Planning is one the most critical roles in the cynical supply chain. Planners decide how much study drugs produce, source package and distribute and when to do so. Consequently, all the clinical supply chain’s performance indicators (waste, costs, inventories, shortage risks, CO2 emissions, etc) are intimately linked to their actions. While systems help, they are not the main driver of a planning organization’s success.

• The 4 “P” (People, Process, Product, Performance) for a successful organisation 

• How to structure a team, including roles and responsibilities to make planning a strategic role 

• What are the essential processes to enable a high-performing CTS planning 

• How to make performance a priority and improve it through planning 

• Illustration through business cases, benchmarks and good practices